Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · Mkt capMarket cap $22.61B · View financials
Snapshot Sep 4, 4:00 PM ET
FY 2025 ·
Decision snapshot: XPO stock price vs SUPN: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at SUPN's multiple
Needs SUPN P/E.
Implied fair value · at XPO's multiple
Needs EPS (TTM) is negative, XPO P/E.
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Multiple discount
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: XPO FY 2025 (ended Dec 31, 2025) · SUPN FY 2025 (ended Dec 31, 2025).
Trendline
Ten fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 87% equity / 13% debt · EV / Revenue 3.15x · EV / EBITDA 35.51x
Capital structure 98% equity / 2% debt · EV / Revenue 3.40x · EV / EBITDA 50.52x
XPO carries the larger enterprise value at $25.71B against $2.45B; XPO trades on the lower EV / Revenue multiple (3.15x vs 3.40x); XPO on the lower EV / EBITDA (35.51x vs 50.52x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
XPO, Inc. · implied price per share
Bear
-$17.35
Base
-$15.65
Bull
-$13.36
SUPERNUS PHARMACEUTICALS, INC. · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
1.83x
0.04x
Net debt / EBITDA
Leverage against operating earnings
4.28x
-1.75x
Cash and equivalents
Liquid reserves on the balance sheet
$310.00M
$128.45M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
C. H. ROBINSON WORLDWIDE, INC.
XPO vs CHRW
Hub Group, Inc.
XPO vs HUBG
SAIA INC
XPO vs SAIA
OLD DOMINION FREIGHT LINE, INC.
XPO vs ODFL
FEDEX CORP
XPO vs FDX
UNITED PARCEL SERVICE INC
XPO vs UPS
Jazz Pharmaceuticals plc
XPO vs JAZZ
INCYTE CORP
XPO vs INCY
ANI PHARMACEUTICALS INC
XPO vs ANIP
Vanda Pharmaceuticals Inc.
XPO vs VNDA
Harmony Biosciences Holdings, Inc.
XPO vs HRMY
$3.41B
$43.80M
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.
